Emtricitabina

Emtricitabina Uses, Dosage, Side Effects, Food Interaction and all others data.

Emtricitabina is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabina is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.

Emtricitabina was granted FDA approval on 2 July 2003.

Emtricitabina is a cytidine analog that competes with the natural substrate of HIV-1 reverse transcriptase to be incorporated into newly formed DNA, terminating its transcription. It is administered once daily so it has a long duration of action. Patients should be counselled regarding the risk of lactic acidosis and hepatomegaly with steatosis.

Trade Name Emtricitabina
Availability Prescription only
Generic Emtricitabine
Emtricitabine Other Names Emtricitabin, Emtricitabina, Emtricitabine, Emtricitabinum
Related Drugs Biktarvy, Truvada, tenofovir, ritonavir, zidovudine, abacavir, lamivudine, Complera, Atripla, Stribild
Type
Formula C8H10FN3O3S
Weight Average: 247.247
Monoisotopic: 247.042690096
Protein binding

Emtricitabine is 5 mainly serum albumin.[A19948]

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Emtricitabina
Emtricitabina

Uses

Emtricitabina is a nucleoside reverse transcriptase inhibitor used for the treatment and prophylaxis of HIV.

Emtricitabina is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.

Emtricitabina is also used to associated treatment for these conditions: HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection

How Emtricitabina works

Emtricitabina is a cytidine analog which, when phosphorylated to emtricitabine 5'-triphosphate, competes with deoxycytidine 5'-triphosphate for HIV-1 reverse transcriptase. As HIV-1 reverse transcriptase incorporates emtricitabine into forming DNA strands, new nucleotides are unable to be incorporated, leading to viral DNA chain termination. Inhibition of reverse transcriptase prevents transcription of viral RNA into DNA, therefore the virus is unable to incorporate its DNA into host DNA and replicate using host cell machinery. This reduces viral load.

Toxicity

The LD50 of emtricitabine is not readily available.[9019,L9818]

Symptoms of emtricitabine toxicity include hepatotoxicity with steatosis, as well as lactic acidosis. Treat overdose with symptomatic and supportive measures, including hemodialysis.

Food Interaction

  • Take with or without food. The absorption is unaffected by food.

Emtricitabina Disease Interaction

Major: hepatitis BModerate: hemodialysis, renal dysfunction

Volume of Distribution

The apparent central volume of distribution is 42.3L and the peripheral volume of distribution is 55.4L.

Elimination Route

Emtricitabina reaches a Cmax of 1.8±0.7µg/mL with a Tmax of 1-2 hours, and has an AUC of 10±3.1µg*hr/mL. The bioavailability of emtricitabine capsules is 93% and the bioavailability of the oral solution is 75%. Taking emtricitabine with food decreases the Cmax by 29%.[L9019

Half Life

The half life of emtricitabine is approximately 10 hours.

Clearance

Emtricitabina has an apparent elimination rate of 15.1L/h. This rate is closely linked to creatinine clearance.

Elimination Route

Emtricitabina is 86% recovered in the urine and 14% recovered in feces. 13% of the dose is recovered in the urine as metabolites; 9% as 3'-sulfoxide diastereomers and 4% as 2'-O-glucuronide.

Innovators Monograph

You find simplified version here Emtricitabina

*** Taking medicines without doctor's advice can cause long-term problems.
Share